On April 16, 2026, the FDA published a Federal Register notice announcing a Pharmacy Compounding Advisory Committee (PCAC) meeting on July 23–24, 2026 at the White Oak Campus. The committee will consider seven peptide-related bulk drug substances for potential inclusion on the Section 503A Bulk Drug Substances List — the federal list that determines which substances licensed compounding pharmacies may use to compound patient-specific prescriptions.
This is the first substantive 503A review of these molecules since the April 23, 2026 reclassification removed them from the Category 2 restricted list. Several Limitless protocol elements are on the docket. Several are not. The first job of any honest physician right now is to tell patients exactly which is which.
What is on the agenda.
| Day | Substance | On the Limitless menu? |
|---|---|---|
| Day 1 — Thursday, July 23, 2026 | ||
| BPC-157 (free base / acetate) | Tendon, ligament, gut, and recovery protocols — yes, currently dispensed via 503A. | |
| KPV (free base / acetate) | Not currently on the menu. Watching-only research posture (see KPV brief). | |
| TB-500 (free base / acetate) | Paired with BPC-157 in the recovery protocol — yes. | |
| MOTS-c (free base / acetate) | Mitochondrial-efficiency / AMPK protocol — yes. | |
| Day 2 — Friday, July 24, 2026 | ||
| Emideltide (DSIP — Delta Sleep-Inducing Peptide) | Not on the menu. No active interest. | |
| Epitalon (Ala-Glu-Asp-Gly) | Not on the menu. A longevity/telomerase-claim peptide whose marketing badly outruns its human evidence — research-watch posture only. See the post-PCAC roadmap. | |
| Semax | Discussed in the cognitive peptide review; not on the default menu. | |
That is the full slate — seven substances across two days. Four of them (BPC-157, KPV, TB-500, MOTS-c) are scheduled for day one; three (Emideltide, Epitalon, Semax) for day two. Three of the seven are already part of the Limitless protocol library or are explicitly tracked in our research; the other four are not on our menu and, with the exception of KPV, are not under active consideration.
A detail almost no one is explaining: free base vs. acetate.
When the FDA posted the confirmed agenda, it listed each of the day-one peptides not as one item but as two separate nominations — a free-base form and an acetate salt form. BPC-157 (free base) and BPC-157 (acetate) are being evaluated as distinct bulk drug substances; the same is true for KPV, TB-500, and MOTS-c. That is eight separate nomination records behind the four day-one names.
Why this matters to a patient rather than only to a chemist: the committee can reach different conclusions on the two salt forms of the same peptide. A favorable read on one form and an unfavorable read on the other would shape exactly which formulation a 503A pharmacy can compound — and therefore which version your physician can prescribe. It is the kind of granular distinction that gets flattened in most "the FDA is reviewing seven peptides" coverage, and it is precisely the level at which compounding access is actually decided. Limitless tracks the docket at the salt-form level, not the headline level.
What is not on the agenda — and why that matters.
CJC-1295 and Ipamorelin are not on this agenda. They are growth-hormone secretagogues sitting in a different regulatory queue. CJC-1295 was removed from Category 2 and referred to PCAC for future evaluation, but the FDA's current posture is that it remains classified as a developmental drug and is not legal for human compounding until full notice-and-comment rulemaking concludes — a process that, under standard timelines, takes more than a year after a favorable PCAC vote. Tesamorelin and sermorelin are FDA-approved analogs and are not part of the 503A bulks question at all.
The practical implication for Limitless: our growth-hormone-axis protocol is built around tesamorelin (FDA-approved) as the lead GHRH analog, with the standing peptide stack designed to be insulated against an adverse CJC-1295 outcome. We are not waiting on this PCAC meeting to know what to do with growth-hormone secretagogues.
This is the first of two reviews — a second meeting is already scheduled.
The July 23–24 meeting is not the FDA's last word on compounded peptides. The agency has signaled a second PCAC meeting before the end of February 2027 to evaluate an additional five peptide substances; the exact slate for that meeting has not yet been published. What this tells a patient is straightforward: peptide regulation in 2026–2027 is a rolling process, not a single verdict. A molecule absent from the July docket is not excluded — it may simply be queued for the next round. Limitless's posture is built for the rolling process rather than for any one meeting: FDA-approved molecules at the core, 503A-compounded peptides with credible dossiers around them, and a written internal monitoring file that we update after every PCAC action. We will publish a plain-language read of the early-2027 slate as soon as the FDA posts it.
What an include / exclude / table vote would actually mean.
The committee can recommend three things for each substance: include it on the 503A bulks list, exclude it, or table the vote pending additional information. Below is what each outcome would mean for the four molecules where Limitless has a direct stake.
If BPC-157 is included.
BPC-157 has by far the deepest preclinical and emerging human dossier of the four. An "include" vote would clear the path for durable 503A compounding once FDA rulemaking concludes. Limitless protocols continue uninterrupted; our 503A partner formulary stays open.
The April 23 reclassification holds for now, but the durable shelf status becomes uncertain. We would extend the 503A partner audit, run a parallel sourcing plan, and prepare a transition memo for patients on active BPC-157 + TB-500 cycles. No patient is left without a plan.
Status quo continues. We add the committee's specific concerns to our internal monitoring file and update our patient-facing BPC-157 brief within seven days of the meeting.
If TB-500 is included.
Thymosin β4 has a smaller but coherent literature, especially around tendinopathy and wound healing. Inclusion would normalize the BPC-157 + TB-500 combination protocol that Limitless and most peptide-literate practices use.
The combined recovery protocol shifts to BPC-157 monotherapy where dispensable, with a documented tradeoff conversation in clinic. We do not improvise around an exclusion.
If MOTS-c is included.
MOTS-c is a mitochondrially encoded peptide with provocative metabolic biology but a much thinner human-data set than BPC-157. An include vote would be a signal that the committee is willing to act on mechanistic evidence with limited human exposure data. Limitless prescribing posture would not change — we already dispense MOTS-c under transparent informed consent about evidence tier.
We pause new MOTS-c initiations and complete ongoing courses with full disclosure of the regulatory change. We do not import gray-market replacement; the standing rule is 503A or nothing.
If KPV is included.
KPV is not currently on the Limitless menu. An include vote would open the door to a structured pilot for select GI-symptom patients under transparent informed consent — only after we have a 503A partner formulation and a defined indication and endpoint. We are not in a hurry. See the full KPV evidence brief for what the preclinical literature does and does not support.
The two-step after the vote.
Patients should understand that even a favorable PCAC recommendation is not the end of the regulatory process. A "yes" vote sends the substance into FDA notice-and-comment rulemaking — a formal procedure that frequently takes more than a year. In the interim, the April 23 reclassification controls the day-to-day legal status; PCAC's recommendation shapes the durable shelf status. Both matter. They operate on different clocks.
What this means in practice: a favorable July vote on BPC-157 does not mean BPC-157 will be on the 503A bulks list in August. A favorable vote means the path is open and the rulemaking can begin. Our continuity plan is built around the assumption that the April 23 reclassification is the operational regime through 2026 and into early 2027, with the PCAC outcomes shaping how robust the post-rulemaking shelf looks.
What Limitless will do next.
- Pre-vote: Update the legal-status briefing by July 8, the day before the July 9 advance-distribution cutoff, with anything new from the FDA's pre-meeting materials (which are typically posted two business days before the meeting).
- During the meeting: Live-listen and take physician notes; no preemptive statements.
- Post-vote (within 7 days): Ship a recap update to /peptides-legal-2026 and to the relevant research articles (BPC-157, KPV) with the actual outcomes and Limitless's operational response.
- Post-vote (within 30 days): Patient-by-patient email to anyone on an affected protocol if any operational change is required, with the specific change for them in writing.
The bottom line.
The July 23–24 PCAC meeting matters. It does not, however, change the floor under our patients' care between now and the next year of rulemaking. Limitless's protocols are built around FDA-approved molecules (tesamorelin, tadalafil, testosterone), 503A-compounded peptides with credible PCAC dossiers (BPC-157, TB-500, MOTS-c), and a sourcing posture (503A only, two pharmacy partners by June 1) that absorbs whatever the committee decides. If you are a current patient, your protocol is not in suspense. If you are a prospective patient, the calmest answer to "is this regulatory uncertainty going to bite me?" is also the most accurate one: the practice has been designed to operate cleanly through exactly this kind of regulatory window.
If this matters to your care, say so on the record.
The PCAC accepts written public comment through Regulations.gov until July 22, 2026. Comments received by July 9 are distributed to committee members before the vote — so file by July 9 if you want yours read in advance. Comments from patients and prescribing physicians carry meaningful weight in how the committee weighs the evidence. The right approach is brief, specific, and grounded in your own experience — not advocacy boilerplate.
Submit at regulations.gov referencing the FDA's July 23–24, 2026 PCAC docket. Identify yourself honestly. Personal experience outperforms talking points.